The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DEOXYGLUCOSE; DOPAMINE; LEVODOPA; NALTREXONE; RIMONABANT;

ANIMAL EXPERIMENT; BASAL GANGLION; CELL COMMUNICATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG INDUCED DISEASE; DYSKINESIA; METABOLISM; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

CELL COMMUNICATION; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE;

EID: 0034080893     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;i: 292-296
2. Rinne UK. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1983;95(Suppl): 19-26
3. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91
4. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115
5. Rascol A, Guiraud B, Montastruc JL, et al. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150
6. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023
7. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13:234-241
8. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonist on the parkinsonian primate brain. Brain 1992;115:809-824
9. Vila M, Levy R, Herrero M-T, et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridisation study of cytochrome oxidase subunit mRNA. J Neurosci 1997;17:765-773
10. Mata M, Fink DJ, Gainer H, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980;34:213-215
11. Schwartz WJ, Smith CB, Davidsen L, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979;219:316-318
12. Theurich M, Muller CM, Scheich H. 2-Deoxyglucose accumulation parallels extracellularly recorded spike activity in the avian auditory system. Brain Res 1984;322:157-161
13. Wong-Riley MTT. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 1989;12:94-101
14. Smith Y, Bolam JP. The output neurones and the dopaminergic neurones of the substantia nigra receive a GABA input from the globus pallidus in the rat. J Comp Neurol 1989;296:47-64
15. Mouroux M, Feger J. Evidence that the parafascicular projection to the subthalamic nucleus is glutamatergic. Neuroreport 1993;4: 613-615
16. Mouroux M, Hassani OK, Feger J. Electrophysiological study of the excitatory parafascicular projection to the subthalamic nucleus and evidence for ipsi- and contralateral controls. Neuroscience 1995;67:399-407
17. Rouzaire-Dubois B, Scarnati E. Bilateral corticosubthalamic nucleus projections: an electrophysiological study in rat with chronic cerebral lesions. Neuroscience 1985;15:69-79
18. 14C]-GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Exp Neurol 1991;113:171-181
19. Levy R, Hazrati L-N, Herrero M-T, et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 1997;76:335-343
20. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65: 59-70
21. Martin JP. Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys). Brain 1927;50:637-651
22. Hammond C, Feger J, Biolac B, Souteyrend JP. Experimental hemiballismus produced by unilateral kainic acid lesion in the corpus Luysii. Brain Res 1979;171:577-580
23. Whittier JR, Mettler FA. Studies on the subthalamus of the rhesus monkey II. Hyperkinesia and other physiologic effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J Comp Neurol 1949;90:319-372
24. Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res 1985;339:346-350
25. Samuel M, Caputo E, Brooks DJ, et al. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain 1998;121:59-75
26. Merello M, Cammarota A, Nouzeilles MI, et al. Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test. Mov Disord 1998;13:533-535
27. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346:1383-1387
28. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996;40:355-366
29. Gross C, Rougier A, Guehl D, et al. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. J Neurosurg 1997;87:491-498
30. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876
31. 3H]-5HT from slices of rat globus pallidus. Biochem Pharmacol 1987;36:1738-1741
32. Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994;125:65-71
33. Hille CJ, Fox SH, Peggs D, et al. A novel therapeutic approach to the symptomatic treatment of Parkinson's disease based on activation of delta opioid receptors. Proc Soc Neurosci (USA) 1997;3: 291.5 (Abstract)
34. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997;144:423-432
35. Duty S, Henry B, Crossman AR, Brorchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp Neurol 1998;150:223-234
36. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine or lisuride administration on pre-proenkephalin-A and pre-proenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 1999;155:204-220
37. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-158
38. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
39. Gerfen CR, McGinty JF, Young III WS. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: in situ hybridisation histochemical analysis. J Neurosci 1991;11:1016-1031
40. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output neurons of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118
41. Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the ouput regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995; 683:102-108
42. Hill MP, Hille CJ, Maneuf YP, Brotchie JM. Modulation of glutamare transmission in the basal ganglia by enadoline, a selective kappa-opioid receptor agonist, in the marmoset and rat. In: Ohye O, Kimura M, McKenzie J, eds. The basal ganglia V. New York: Plenum Press; 1996:165-171
43. 2-adrenergic receptor antagonist idazoxan reduces L-DOPA-induced dyskinesia and increases the anti-parkinsonian actions of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 1998;13(Suppl 2):2.034 (Abstract)
44. 2 antagonist, idazoxan, in patients with Parkinson's disease [abstract]. Mov Disord 1997;12:111
45. Gomez-Mancilla B, Bédard PJ. Effect of non-dopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427